Inhibitory Effects of Emodin, Baicalin, Schizandrin and Berberine on HefA Gene: Treatment of Helicobacter Pylori-induced Multidrug Resistance

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2015 Apr 21

PMID 25892872

Citations 27

Authors

Yan-Qiang Huang

Gan-Rong Huang

Ming-Hui Wu

Hua-Ying Tang

Zan-Song Huang

Xi-Han Zhou

Wen-Qiang Yu

Jian-Wei Su

Xiao-Qiang Mo

Bing-Pu Chen

Li-Juan Zhao

Xiao-Feng Huang

Hong-Yu Wei

Lian-Deng Wei

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate the inhibitory effects of emodin, baicalin, etc. on the hefA gene of multidrug resistance (MDR) in Helicobacter pylori (H. pylori).

Methods: The double dilution method was used to screen MDR H. pylori strains and determine the minimum inhibitory concentrations (MICs) of emodin, baicalin, schizandrin, berberine, clarithromycin, metronidazole, tetracycline, amoxicillin and levofloxacin against H. pylori strains. After the screened MDR stains were treated with emodin, baicalin, schizandrin or berberine at a 1/2 MIC concentration for 48 h, changes in MICs of amoxicillin, tetracycline, levofloxacin, metronidazole and clarithromycin were determined. MDR strains with reduced MICs of amoxicillin were selected to detect the hefA mRNA expression by real-time quantitative PCR.

Results: A total of four MDR H. pylori strains were screened. Treatment with emodin, baicalin, schizandrin and berberine significantly decreased the MICs of amoxicillin and tetracycline against some strains, decreased by 1 to 2 times, but did not significantly change the MICs of clarithromycin, levofloxacin, and metronidazole against MDR strains. In the majority of strains with reduced MICs of amoxicillin, hefA mRNA expression was decreased; one-way ANOVA (SPSS 12.0) used for comparative analysis, P < 0.05.

Conclusion: Emodin, baicalin, schizandrin and berberine significantly decreased the MICs of amoxicillin and tetracycline against some H. pylori strains, possibly by mechanisms associated with decreasing hefA mRNA expression.

Citing Articles

Green Chemistry Within the Circular Bioeconomy to Harness Chestnut Burr Extract's Synergistic Antimicrobial Activity Against .

Schiavone M, Barletta R, Trezza A, Geminiani M, Millucci L, Figura N Molecules. 2025; 30(2).

PMID: 39860194 PMC: 11767412. DOI: 10.3390/molecules30020324.

Efficacy and safety of LiWei capsule in chronic non-atrophic gastritis with erosions: a randomized controlled trial.

Cui D, Geng X, Wang J, Han X, Huang Z, Jiang M Sci Rep. 2025; 15(1):1620.

PMID: 39794448 PMC: 11724083. DOI: 10.1038/s41598-025-85122-y.

Antibacterial activities of anthraquinones: structure-activity relationships and action mechanisms.

Qun T, Zhou T, Hao J, Wang C, Zhang K, Xu J RSC Med Chem. 2023; 14(8):1446-1471.

PMID: 37593578 PMC: 10429894. DOI: 10.1039/d3md00116d.

Study of the Effect of Baicalin from on the Gastrointestinal Tract Normoflora and .

Dmitrieva A, Kozlova O, Atuchin V, Milentieva I, Vesnina A, Ivanova S Int J Mol Sci. 2023; 24(15).

PMID: 37569279 PMC: 10419321. DOI: 10.3390/ijms241511906.

Progress in traditional Chinese medicine against chronic gastritis: From chronic non-atrophic gastritis to gastric precancerous lesions.

Yang L, Liu X, Zhu J, Zhang X, Li Y, Chen J Heliyon. 2023; 9(6):e16764.

PMID: 37313135 PMC: 10258419. DOI: 10.1016/j.heliyon.2023.e16764.

References

Wu J, Hu D, Wang K . [Study of Scutellaria baicalensis and Baicalin against antimicrobial susceptibility of Helicobacter pylori strains in vitro]. Zhong Yao Cai. 2008; 31(5):707-10. View

Liu Z, Zheng P, Yang P . Efflux pump gene hefA of Helicobacter pylori plays an important role in multidrug resistance. World J Gastroenterol. 2008; 14(33):5217-22. PMC: 2744013. DOI: 10.3748/wjg.14.5217. View

Cid T, Fernandez M, Benito Martinez S, Jones N . Pathogenesis of Helicobacter pylori infection. Helicobacter. 2013; 18 Suppl 1:12-7. DOI: 10.1111/hel.12076. View

Zhang L, Yang L, Yang L . [Relation between Helicobacter pylori and pathogenesis of chronic atrophic gastritis and the research of its prevention and treatment]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 1992; 12(9):521-3, 515-6. View

Zhang Z, Liu Z, Zheng P, Tang F, Yang P . Influence of efflux pump inhibitors on the multidrug resistance of Helicobacter pylori. World J Gastroenterol. 2010; 16(10):1279-84. PMC: 2839183. DOI: 10.3748/wjg.v16.i10.1279. View

Ma F, Chen Y, Li J, Qing H, Wang J, Zhang Y . Screening test for anti-Helicobacter pylori activity of traditional Chinese herbal medicines. World J Gastroenterol. 2010; 16(44):5629-34. PMC: 2992683. DOI: 10.3748/wjg.v16.i44.5629. View

Gisbert J . [Helicobacter pylori-related diseases]. Gastroenterol Hepatol. 2012; 35 Suppl 1:12-25. DOI: 10.1016/S0210-5705(12)70030-4. View

Bu Y, Lee K, Jung H, Moon S . Therapeutic effects of traditional herbal medicine on cerebral ischemia: a perspective of vascular protection. Chin J Integr Med. 2013; 19(11):804-14. DOI: 10.1007/s11655-013-1341-2. View

Chang C, Huang W, Lai C, Hsu Y, Yao Y, Chen T . Development of novel nanoparticles shelled with heparin for berberine delivery to treat Helicobacter pylori. Acta Biomater. 2010; 7(2):593-603. DOI: 10.1016/j.actbio.2010.08.028. View

10.

Kim M, Kim N, Kim S, Jo H, Shin C, Lee S . Long-term follow-up Helicobacter pylori reinfection rate and its associated factors in Korea. Helicobacter. 2012; 18(2):135-42. DOI: 10.1111/hel.12018. View

11.

Abdollahi H, Savari M, Zahedi M, Darvish Moghadam S, Abasi M . Detection of A2142C, A2142G, and A2143G Mutations in 23s rRNA Gene Conferring Resistance to Clarithromycin among Helicobacter pylori Isolates in Kerman, Iran. Iran J Med Sci. 2013; 36(2):104-10. PMC: 3556758. View

12.

Lin J, Huang W . A systematic review of treating Helicobacter pylori infection with Traditional Chinese Medicine. World J Gastroenterol. 2009; 15(37):4715-9. PMC: 2754520. DOI: 10.3748/wjg.15.4715. View

13.

Hsu S, Chung J . Anticancer potential of emodin. Biomedicine (Taipei). 2020; 2(3):108-116. PMC: 7104001. DOI: 10.1016/j.biomed.2012.03.003. View

14.

Hu F . [A multicenter study of Chinese patent medicine wenweishu/yangweishu in the treatment of Helicobacter pylori positive patients with chronic gastritis and peptic ulcer]. Zhonghua Yi Xue Za Zhi. 2010; 90(2):75-8. View

15.

Vega A, Cortinas T, Puig O, Silva H . Molecular characterization and susceptibility testing of Helicobacter pylori strains isolated in western Argentina. Int J Infect Dis. 2010; 14 Suppl 3:e85-92. DOI: 10.1016/j.ijid.2009.11.022. View

16.

Malfertheiner P, Megraud F, OMorain C, Atherton J, Axon A, Bazzoli F . Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut. 2012; 61(5):646-64. DOI: 10.1136/gutjnl-2012-302084. View

17.

Gao H, Sheng H . [Genotyping of mutations contributing to antibiotic resistance and Helicobacter pylori eradication therapy]. Zhonghua Yi Xue Za Zhi. 2012; 92(10):657-8. View

18.

Wueppenhorst N, Stueger H, Kist M, Glocker E . Identification and molecular characterization of triple- and quadruple-resistant Helicobacter pylori clinical isolates in Germany. J Antimicrob Chemother. 2009; 63(4):648-53. DOI: 10.1093/jac/dkp003. View

19.

Thirumurthi S, Graham D . Helicobacter pylori infection in India from a western perspective. Indian J Med Res. 2012; 136(4):549-62. PMC: 3516022. View

20.

Vilaichone R, Yamaoka Y, Shiota S, Ratanachu-Ek T, Tshering L, Uchida T . Antibiotics resistance rate of Helicobacter pylori in Bhutan. World J Gastroenterol. 2013; 19(33):5508-12. PMC: 3761104. DOI: 10.3748/wjg.v19.i33.5508. View